Acepodia Presents Positive Interim Phase 1 Feasibility Data for Antibody Cell Effector Therapy, ACE1702, in Advanced HER2-Positive Tumors
Interim results from ongoing Phase 1 dose-escalation study demonstrate safety and tolerability of repeat dosing…
SeoulCeuticals Publishes First Official Layering Guide for Volufiline Snail Mucin Serum, Identifying Retinol Sequencing as the Cause of Preventable Irritation for Millions of Users